4//SEC Filing
Israel Biotech Fund II, L.P. 4
Accession 0001178913-24-000480
CIK 0001100397other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 2:16 PM ET
Size
44.9 KB
Accession
0001178913-24-000480
Insider Transaction Report
Form 4
Israel Biotech Fund I, L.P.
10% Owner
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,926,221$770,488→ 11,044,282 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,586,905$3,224,577→ 25,130,903 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,926,221→ 13,661,159 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,926,221 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−4,237,687→ 18,996,000 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (4,237,687 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−3,887,438→ 11,724,938 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (3,887,438 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,295,813→ 14,758,313 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,295,813 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,437,500→ 7,837,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,437,500 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,062,500→ 13,462,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,062,500 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+4,237,687$1,695,075→ 18,359,495 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+3,887,438$1,554,975→ 14,931,720 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,295,813$518,325→ 19,655,308 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,437,500$3,375,000→ 23,369,220 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,707,581$3,375,000→ 20,661,639 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,062,500$3,225,000→ 27,717,808 total(indirect: See footnote)
Israel Biotech Fund II, L.P.
10% Owner
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,926,221$770,488→ 11,044,282 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+4,237,687$1,695,075→ 18,359,495 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,295,813→ 14,758,313 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,295,813 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,062,500→ 13,462,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,062,500 underlying) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,586,905$3,224,577→ 25,130,903 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,926,221→ 13,661,159 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,926,221 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−4,237,687→ 18,996,000 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (4,237,687 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+3,887,438$1,554,975→ 14,931,720 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,295,813$518,325→ 19,655,308 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,437,500$3,375,000→ 23,369,220 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,707,581$3,375,000→ 20,661,639 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,062,500$3,225,000→ 27,717,808 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−3,887,438→ 11,724,938 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (3,887,438 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,437,500→ 7,837,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,437,500 underlying)
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+4,237,687$1,695,075→ 18,359,495 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,437,500$3,375,000→ 23,369,220 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−4,237,687→ 18,996,000 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (4,237,687 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−3,887,438→ 11,724,938 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (3,887,438 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,295,813→ 14,758,313 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,295,813 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,062,500→ 13,462,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,062,500 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,295,813$518,325→ 19,655,308 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,062,500$3,225,000→ 27,717,808 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,926,221→ 13,661,159 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,926,221 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,926,221$770,488→ 11,044,282 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+3,887,438$1,554,975→ 14,931,720 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,707,581$3,375,000→ 20,661,639 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,586,905$3,224,577→ 25,130,903 total(indirect: See footnote) - Exercise/Conversion
Warrants
2024-02-07−8,437,500→ 7,837,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,437,500 underlying)
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+3,887,438$1,554,975→ 14,931,720 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,707,581$3,375,000→ 20,661,639 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,926,221$770,488→ 11,044,282 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+4,237,687$1,695,075→ 18,359,495 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,295,813$518,325→ 19,655,308 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,437,500$3,375,000→ 23,369,220 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,062,500$3,225,000→ 27,717,808 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−4,237,687→ 18,996,000 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (4,237,687 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,295,813→ 14,758,313 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,295,813 underlying) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,586,905$3,224,577→ 25,130,903 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,926,221→ 13,661,159 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,926,221 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−3,887,438→ 11,724,938 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (3,887,438 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,437,500→ 7,837,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,437,500 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,062,500→ 13,462,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,062,500 underlying)
I.B.F. Management Ltd.
10% Owner
Transactions
- Exercise/Conversion
Warrants
2024-02-07−8,062,500→ 13,462,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,062,500 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,926,221$770,488→ 11,044,282 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+4,237,687$1,695,075→ 18,359,495 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+3,887,438$1,554,975→ 14,931,720 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+1,295,813$518,325→ 19,655,308 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,437,500$3,375,000→ 23,369,220 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,707,581$3,375,000→ 20,661,639 total(indirect: See footnote) - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-02-07$0.40/sh+8,062,500$3,225,000→ 27,717,808 total(indirect: See footnote) - Tax Payment
Common Stock, par value $0.001 per share
2024-02-07$1.25/sh−2,586,905$3,224,577→ 25,130,903 total(indirect: See footnote) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,926,221→ 13,661,159 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,926,221 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−4,237,687→ 18,996,000 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (4,237,687 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−3,887,438→ 11,724,938 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (3,887,438 underlying) - Exercise/Conversion
Convertible Promissory Note
2024-02-07−1,295,813→ 14,758,313 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (1,295,813 underlying) - Exercise/Conversion
Warrants
2024-02-07−8,437,500→ 7,837,500 total(indirect: See footnote)Exercise: $0.40From: 2023-11-17Exp: 2028-11-17→ Common Stock (8,437,500 underlying)
Footnotes (6)
- [F1]On 11/17/2023, Issuer issued to Israel Biotech Fund I, L.P. ("IBF 1") and IBF II Israel Biotech Fund II, L.P. ("IBF 2") Senior Convertible Promissory Notes, with a principal amount of $750,000 and $1,650,000, respectively (the "Notes"), and, in connection therewith, warrants to purchase 2,812,500 shares of Common Stock and 6,187,500 shares of Common Stock, respectively, at an exercise price of $0.40 per share, subject to adjustments (the "Warrants"). As more fully described in a Schedule 13D/A filed by the Reporting Persons on 2/12/2024 (the "Schedule 13D/A"), on 2/7/2024 the Notes were converted into 1,926,221 shares of Common Stock and 4,237,687 shares of Common Stock, respectively, which number of shares represents the aggregate principal amount plus aggregate accrued interest due on the Notes, divided by $0.40 (the "Conversion Price").
- [F2]The reported securities in this row are held of record by IBF 1. Israel Biotech Fund GP Partners, L.P. ("IBF I GP"), a Cayman Islands Exempted Limited Partnership, is the general partner of IBF 1. I.B.F Management Ltd. ("IBF Management"), an Israeli private company, is the management company of IBF I GP. By virtue of such relationships, IBF 1 GP and IBF Management may be deemed to have shared voting and investment power with respect to the securities held of record by IBF 1. Each of IBF 1 GP and IBF Management disclaims beneficial ownership of the securities held by IBF 1, except to the extent of their pecuniary interest therein, if any.
- [F3]The reported securities in this row are held of record by IBF 2. Israel Biotech Fund GP Partners II, L.P. ("IBF II GP"), a Cayman Islands Exempted Limited Partnership, is the general partner of IBF 2. IBF Management is the management company of IBF 2 GP. By virtue of such relationships, IBF 2 GP and IBF Management may be deemed to have shared voting and investment power with respect to the securities held of record by IBF 2. Each of IBF 2 GP and IBF Management disclaims beneficial ownership of the securities held by IBF 2, except to the extent of their pecuniary interest therein, if any.
- [F4]On 11/17/2023, Issuer issued to IBF 1 and IBF II Amended and Restated Senior Secured Convertible Promissory Notes with a principal amount of $1,500,000 and $500,000, respectively (the "A&R Notes"), and, in connection therewith, warrants to purchase 5,625,000 shares of Common Stock and 1,875,000 shares of Common Stock, respectively, at an exercise price of $0.40 per share, subject to adjustments (the "A&R Warrants"). As more fully described in the Schedule 13D/A, on 2/7/2024, the A&R Notes were converted into 3,887,438 shares of Common Stock and 1,295,813 shares of Common Stock, respectively, which number of shares represents the aggregate principal amount plus aggregate accrued interest due on the Notes, divided by the Conversion Price.
- [F5]As more fully described in the Schedule 13D/A, (i) IBF I exercised an aggregate of 8,437,500 Warrants and A&R Warrants it holds (through a "cashless exercise") and, on 2/7/2024, the Issuer issued to IBF I a total of 5,729,919 shares of Common Stock in respect thereto (which reflects a total of 2,707,581 shares "withheld" by the Issuer in connection with the "cashless exercise" of such warrants to satisfy the aggregate exercise price of such warrants, based on the daily VWAP of the shares of Common Stock of $1.2465), and (ii) IBF II exercised an aggregate of 8,062,500 Warrants and A&R Warrants it holds (through a cashless exercise) and, on 2/7/2024, the Issuer issued to IBF II a total of 5,475,595 shares of Common Stock in respect thereto (which reflects a total of 2,586,905 shares "withheld" by the Issuer in connection with the "cashless exercise" of such warrants, based on the daily VWAP of the shares of Common Stock of $1.2465).
- [F6]The remaining derivative securities reported in this row reflect the rights of IBF I and IBF II to purchase senior convertible promissory notes on the same terms (including with respect to warrant coverage) as the Notes, as previously reported on Form 4 filed by the Reporting Persons on 11/21/2023.
Documents
Issuer
Ayala Pharmaceuticals, Inc.
CIK 0001100397
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001782947
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 2:16 PM ET
- Size
- 44.9 KB